After announcing cooperation, Kazia Therapeutics Limited (NASD: KZIA) is climbing the charts today, up 7.29% to trade at $0.5901 at the last check.
Who will KZIA be cooperating with?
In order to investigate cutting-edge applications of paxalisib in solid tumors, Kazia Therapeutics (KZIA) has partnered with QIMR Berghofer Medical Research Institute, one of Australia’s premier cancer research institutions.
PI3K/mTOR inhibitor paxalisib, the company’s flagship asset, is a target for Kazia Therapeutics’ research in solid tumors. The research cooperation intends to expand on earlier work, including the potential application of paxalisib as an immunological moderator in solid malignancies. The continued partnership will expand on earlier studies, such as the application of paxalisib as an immune modulator in the treatment of disorders like breast cancer, which has already resulted in the submission of a patent.
The study creates a significant prospect for paxalisib to be used in conjunction with Keytruda and Opdivo to treat conditions including breast cancer and lung cancer. Such combinations may be able to enhance patient outcomes if they are successful in clinical studies. Following the recent setback in the GBM AGILE study where paxalisib was unable to graduate to stage 2 of the Phase III trial, KZIA recently announced inspiring statistics in an investigational melanoma study, outlining its growing focus on uncovering indications other than brain cancer and brain metastases.
The study findings are scheduled to be published in 1H CY2023, and conversations about potential translation to clinical trials in CY2023 are still continuing. Upon confirmation, it may open the door to the use of paxalisib in conjunction with checkpoint inhibitors like Keytruda and Opdivo for the treatment of solid malignancies including breast and lung cancer.
How will KZIA make use of the results?
Initial in-vitro results showed paxalisib to demonstrate suppression of both the original tumor and metastasis by enhancing the immune response inside the tumor microenvironment, which encouraged Kazia Therapeutics (KZIA). Instead of KZIA’s usual emphasis on brain malignancies, the partnership may be a start toward investigating the applicability of paxalisib in additional cancer indications.